Editorial/mini-review: Vitamin D and prostate cancer

Endocrinology

Volumn 141, Issue 1, 2000, Pages 5-9

  Feldman, D ^a   Zhao, X Y ^a   Krishnan, A V ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CYCLIN DEPENDENT KINASE INHIBITOR; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN P21; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; DRUG DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; EDITORIAL; GENETIC RISK; HISTORY OF MEDICINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; VITAMIN D METABOLISM; ADENOCARCINOMA; ANIMAL; NOTE; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; ANIMALS; CALCITRIOL; HUMANS; MALE; PROSTATIC NEOPLASMS; VITAMIN D;

EID: 85047685564     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.141.1.7341     Document Type: Editorial

References (30)

1. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of bcl-2
2. Vitamin D and prostate cancer
3. Vitamin D and prostate cancer: Biologic interactions and clinical potentials
4. Vitamin D and prostate cancer
5. Vitamin D in the prevention and treatment of prostate cancer
6. Molecular genetics and epidemiology of prostate carcinoma
7. Is Vitamin D deficiency a risk factor for prostate cancer? (Hypothesis)
8. 3 receptors and actions in human prostate cancer cell lines
9. 3 on primary cultures of human prostatic cells
10. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines
11. 3 in the human prostatic carcinoma cell line ALVA 31
12. 3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity
13. 3 and its A ring-modified analogs
14. Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system
15. 3 receptor
16. 3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1
17. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation
18. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin
19. 3 leads to the induced differentiation of the myelomonocytic cell line U937
20. 3 and 9-cis retinoic acid in LNCaP human prostate cancer cells
21. 3 in androgen-responsive LNCaP cells
22. 3 on proliferation of cancer cells in vitro
23. 3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene
24. 3: A new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells
25. Vitamin D is a potent inhibitor of tumor cell-induced angiogenesis
26. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer
27. 3 (calcitriol)
28. 3 on prostatic epithelial cells
29. 3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells